首页 | 本学科首页   官方微博 | 高级检索  
检索        

非小细胞肺癌EGFR-TKI治疗失败后小细胞肺癌转化
引用本文:刘晓晴,郭万峰.非小细胞肺癌EGFR-TKI治疗失败后小细胞肺癌转化[J].临床药物治疗杂志,2013,0(5):1-3,25.
作者姓名:刘晓晴  郭万峰
作者单位:刘晓晴 (军事医学科学院附属解放军307医院肺部肿瘤科 北京 100071); 郭万峰 (军事医学科学院附属解放军307医院肺部肿瘤科 北京 100071);
摘    要:表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌(NSCLC)的耐药分子机制逐渐明了,其中小细胞肺癌(SCLC)转化引发了学者极大关注。这种表型转化和伴发EGFR突变是肿瘤细胞异质性,或是肿瘤干细胞,或是某些分子事件使然,但无论那种机制均是推测且无直接证据。目前临床实践中对这种EGFR-TKI耐药转化为SCLC患者的治疗仅是经验分享,亦无更高级别的证据推荐。

关 键 词:非小细胞肺癌  表皮生长因子受体-酪氨酸激酶抑制剂  小细胞肺癌  耐药性

Transformed from NSCLC into SCLC after failure of EGFR-TKI therapy in patients with NSCLC
Liu Xiao-qing,Guo Wan-feng.Transformed from NSCLC into SCLC after failure of EGFR-TKI therapy in patients with NSCLC[J].Clinical Medication JOurnal,2013,0(5):1-3,25.
Authors:Liu Xiao-qing  Guo Wan-feng
Institution:. Department of Pulmonary Oncology, 307 Hospital of PLA, Beijing 100071, China
Abstract:The genetics mechanisms of drug resistance in non-small cell lung cancer(NSCLC) patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI) were revealed gradually,one of them was surprising-NSCLC transformation into small cell lung cancer(SCLC).This phenotype transformation associated with EGFR gene mutation was resulted from tumor heterogeneity,cancer stem cell or some molecular events,but there was no confirmed evidence for them.Currently,the treatment of the transformation of NSCLC into SCLC after failure of EGFR-TKI therapy is empirical in clinical practice,no higher-level evidence to recommend.
Keywords:Non-small-cell lung cancer  EGFR-TKI  Small-cell lung cancer  Drug resistance
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号